Long‐term outcomes in patients with recurrent human papillomavirus‐positive oropharyngeal cancer after upfront transoral robotic surgery
- 9 August 2020
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 42 (12) , 3490-3496
Abstract
Background Clinical course following failure of human papillomavirus (HPV)‐positive oropharyngeal cancers (HPV + OPC) is poorly understood. This study aims to characterize disease course following failure after transoral robotic surgery (TORS). Methods We identified patients with HPV + OPC‐treated upfront with TORS at our institution from 2007 to 2017. HPV status was confirmed with immunohistochemistry or HPV DNA polymerase chain reaction. Patient characteristics, treatment modalities, and post‐recurrence outcomes were analyzed for the recurrent cohort. Results Of the 317 HPV + OPC patients, 28 (8.8%) experienced recurrence, all of HPV 16/18 subtypes. Median post‐recurrence survival was 19.8 months (range 2.3‐195.8 months) in the 12 locoregional and 16 months (range 2.4‐79.5 months) in the 14 distant failures. Sixteen are alive with a median of 39.8 months (range 5.5‐209.4 months) after retreatment. Conclusion This is one of the largest series evaluating survival following TORS failure in HPV + OPC. Despite failure, long‐term survival and durable remission are possible with single‐modal or multiple‐modal salvage treatment.Keywords
This publication has 21 references indexed in Scilit:
- Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell CarcinomaJournal of Clinical Oncology, 2014
- Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522Journal of Clinical Oncology, 2014
- Tolerability, Toxicity, and Temporal Implications of Transoral Robotic Surgery (TORS) on Adjuvant Radiation Therapy in Carcinoma of the Head and NeckAnnals of Otology, Rhinology & Laryngology, 2014
- Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III TrialJournal of Clinical Oncology, 2010
- Prognostic Implications of HPV in Oropharyngeal CancerNew England Journal of Medicine, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Outcomes following reirradiation of patients with head and neck cancerHead & Neck, 2008
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Results of postoperative reirradiation for recurrent or second primary head and neck carcinomaCancer, 2006